Asset Details
Do you wish to reserve the book?
Management of older or unfit patients with acute myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Management of older or unfit patients with acute myeloid leukemia
Do you wish to request the book?
Management of older or unfit patients with acute myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Management of older or unfit patients with acute myeloid leukemia
2015
Overview
Acute myeloid leukemia (AML) is primarily a disease of older adults, for whom optimal treatment strategies remain controversial. Because of the concern for therapeutic resistance and, in particular, excessive toxicity or even treatment-related mortality, many older or medically unfit patients do not receive AML-directed therapy. Yet, evidence suggests that outcomes are improved if essentially all of these patients are offered AML therapy, ideally at a specialized cancer center. Medical fitness for tolerating intensive chemotherapy can be estimated relatively accurately with multiparameter assessment tools; this information should serve as basis for the assignment to intensive or non-intensive therapy. Until our accuracy in predicting the success of individual therapies improves, all patients should be considered for participation in a randomized controlled trial. Comparisons between individual trials will be facilitated once standardized, improved response criteria are developed, and standard treatment approaches have been defined against which novel therapies can be tested.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Aged
/ Analysis
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Diseases
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - mortality
/ Leukemia, Myeloid, Acute - pathology
/ Male
/ Medicine
/ Oncology
/ Patients
/ Randomized Controlled Trials as Topic
/ review
/ Toxicity
